다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
International journal of cancer: Journal international du cancer, v.127 no.10, 2010년, pp.2467 - 2477
Zhou, Hongyu (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Shen, Tao (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Luo, Yan (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Liu, Lei (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Chen, Wenxing (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Xu, Baoshan (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Han, Xiuzhen (Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA) , Pang, Jia (Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA) , Rivera, Chantal A. (Department of Molecular and Cellular Physiology, Louisian) , Huang, Shile
AI-Helper
Ciclopirox olamine (CPX) is a synthetic antifungal agent clinically used to treat mycoses of the skin and nails. Here, we show that CPX inhibited tumor growth in human breast cancer MDA-MB-231 xenografts. To unveil the underlying mechanism, we further studied the antitumor activity of CPX in cell cu...
Jue, S.G., Dawson, G.W., Brogden, R.N.. Ciclopirox Olamine 1% Cream A Preliminary Review of its Antimicrobial Activity and Therapeutic Use :. Drugs, vol.29, no.4, 330-341.
Bohn, Manfred, Kraemer, Karl Th.. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. Journal of the American Academy of Dermatology, vol.43, no.4, S57-S69.
Arzneimittelforschung Dittmar W 670 23 1973 HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results
Abrams, B.B., Hanel, H., Hoehler, T.. Ciclopirox olamine: A hydroxypyridone antifungal agent. Clinics in dermatology, vol.9, no.4, 471-477.
Gupta, Aditya K.. Ciclopirox: an overview. International journal of dermatology, vol.40, no.5, 305-310.
Mol Cells Leem SH 55 15 2003 10.1016/S1016-8478(23)13707-1 The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae
Farinelli, SE, Greene, LA. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. The Journal of neuroscience : the official journal of the Society for Neuroscience, vol.16, no.3, 1150-1162.
Hoffman, Benjamin D., Hanauske‐Abel, Hartmut M., Flint, Alan, Lalande, Marc. A new class of reversible cell cycle inhibitors. Cytometry, vol.12, no.1, 26-32.
Almeida, Bruno, Sampaio-Marques, Belém, Carvalho, Joana, Silva, Manuel T., Leão, CecÃlia, Rodrigues, Fernando, Ludovico, Paula. An atypical active cell death process underlies the fungicidal activity of ciclopirox olamine against the yeastSaccharomyces cerevisiae. FEMS yeast research, vol.7, no.3, 404-412.
10.1002/(SICI)1097-4547(19991101)58:3<396::AID-JNR5>3.0.CO;2-K
Niewerth, Markus, Kunze, Donika, Seibold, Michael, Schaller, Martin, Korting, Hans Christian, Hube, Bernhard. Ciclopirox Olamine Treatment Affects the Expression Pattern ofCandida albicansGenes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. Antimicrobial agents and chemotherapy, vol.47, no.6, 1805-1817.
Eberhard, Yanina, McDermott, Sean P., Wang, Xiaoming, Gronda, Marcela, Venugopal, Amudha, Wood, Tabitha E., Hurren, Rose, Datti, Alessandro, Batey, Robert A., Wrana, Jeffrey, Antholine, William E., Dick, John E., Schimmer, Aaron D.. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood, vol.114, no.14, 3064-3073.
Arzneimittelforschung Alpermann HG 1328 31 1981 Studies on the pharmacology and toxicology of ciclopiroxolamine
Beevers, Christopher S., Li, Fengjun, Liu, Lei, Huang, Shile. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. International journal of cancer: Journal international du cancer, vol.119, no.4, 757-764.
Malumbres, Marcos, Barbacid, Mariano. Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews. Cancer, vol.9, no.3, 153-166.
Vermeulen, Katrien, Van Bockstaele, Dirk R., Berneman, Zwi N.. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell proliferation, vol.36, no.3, 131-149.
Burkhart, Deborah L., Sage, Julien. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nature reviews. Cancer, vol.8, no.9, 671-682.
Sherr, C J, Roberts, J M. CDK inhibitors: positive and negative regulators of G1-phase progression.. Genes & development, vol.13, no.12, 1501-1512.
Xiong, Yue, Hannon, Gregory J., Zhang, Hui, Casso, David, Kobayashi, Ryuji, Beach, David. p21 is a universal inhibitor of cyclin kinases. Nature, vol.366, no.6456, 701-704.
Lee, Su Jae, Ha, Mahn Joon, Lee, Jeen, Nguyen, PhuongMai, Choi, Yung Hyun, Pirnia, Farzaneh, Kang, Won-Ki, Wang, Xiao-Fan, Kim, Seong-Jin, Trepel, Jane B.. Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 in Human Prostate Carcinoma Cells. The Journal of biological chemistry, vol.273, no.17, 10618-10623.
Youle, Richard J., Strasser, Andreas. The BCL-2 protein family: opposing activities that mediate cell death. Nature reviews. Molecular cell biology, vol.9, no.1, 47-59.
Santamaria, David. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Frontiers in bioscience, vol.11, no.1, 1164-.
Buss, Joan L, Torti, Frank M, Torti, Suzy V. The role of iron chelation in cancer therapy.. Current medicinal chemistry, vol.10, no.12, 1021-1034.
Yuan, Jun, Lovejoy, David B., Richardson, Des R.. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, vol.104, no.5, 1450-1458.
Whitnall, Megan, Howard, Jonathan, Ponka, Prem, Richardson, Des R.. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America, vol.103, no.40, 14901-14906.
Rao, V. Ashutosh, Klein, Sarah R., Agama, Keli K., Toyoda, Eriko, Adachi, Noritaka, Pommier, Yves, Shacter, Emily B.. The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells. Cancer research : the official organ of the American Association for Cancer Research, Inc, vol.69, no.3, 948-957.
10.1182/blood.V75.10.1903.1903
Trachootham, Dunyaporn, Alexandre, Jerome, Huang, Peng. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nature reviews. Drug discovery, vol.8, no.7, 579-591.
Barry, Elly V., Vrooman, Lynda M., Dahlberg, Suzanne E., Neuberg, Donna S., Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Larsen, Eric C., Moghrabi, Albert, Samson, Yvan, Schorin, Marshall A., Cohen, Harvey J., Lipshultz, Steven E., Sallan, Stephen E., Silverman, Lewis B.. Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.26, no.7, 1106-1111.
Lindqvist, Arne, Rodríguez-Bravo, Verónica, Medema, René H.. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. The Journal of cell biology, vol.185, no.2, 193-202.
Polager, S., Ginsberg, D.. E2F - at the crossroads of life and death. Trends in cell biology, vol.18, no.11, 528-535.
Feng, Zhaohui, Hu, Wenwei, Rajagopal, Gunaretnam, Levine, Arnold J.. The tumor suppressor p53: Cancer and aging. Cell cycle, vol.7, no.7, 842-847.
Cheng, Emily H.-Y., Kirsch, David G., Clem, Rollie J., Ravi, Rajani, Kastan, Michael B., Bedi, Atul, Ueno, Kazuyoshi, Hardwick, J. Marie. Conversion of Bcl-2 to a Bax-like Death Effector by Caspases. Science, vol.278, no.5345, 1966-1968.
Grandgirard, D, Studer, E, Monney, L, Belser, T, Fellay, I, Borner, C, Michel, M R. Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2.. The EMBO journal, vol.17, no.5, 1268-1278.
Mol Cancer Ther Kasibhatla S 573 2 2003 Why target apoptosis in cancer treatment?
Tait, S W G, Green, D R. Caspase-independent cell death: leaving the set without the final cut. Oncogene, vol.27, no.50, 6452-6461.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.